Stoke Therapeutics (STOK) Cash from Operations Growth (3y) (2021 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -0.27% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -7.35% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 16.85% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 52.90% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 96.08% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 6.22% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.23% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -37.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -37.43% |
| Mar 31, 2026 | -41.56% |
| Dec 31, 2025 | -10.83% |
| Sep 30, 2025 | -11.25% |
| Jun 30, 2025 | -8.45% |
| Mar 31, 2025 | 59.50% |
| Dec 31, 2024 | -12.57% |
| Sep 30, 2024 | -13.76% |
| Jun 30, 2024 | -3.35% |
| Mar 31, 2024 | -6.85% |
| Dec 31, 2023 | -23.62% |
| Sep 30, 2023 | -16.66% |
| Jun 30, 2023 | -31.23% |
| Mar 31, 2023 | -25.63% |
| Dec 31, 2022 | -29.93% |
| Sep 30, 2022 | -39.94% |
| Jun 30, 2022 | -47.00% |
| Mar 31, 2022 | 91.06% |
| Dec 31, 2021 | -66.61% |
| Sep 30, 2021 | -69.01% |